Patients with acute myeloid leukemia (AML) who were more than 60 years of age received treatment to induce a complete remission that consisted of cytarabine and daunorubicin; the latter was given at a dose of either 45 mg per square meter of body-surface area (the conventional dose of the drug) or 90 mg per square meter. As compared with patients who received the conventional dose of daunorubicin, those who received the high dose had a significantly higher rate of complete remission without an increase in toxic effects.

Patients with AML who were between 17 and 60 years of age were randomly assigned to receive induction therapy with the standard dose of daunorubicin or twice the standard dose; the two groups also received a standard dose of cytarabine. Rates of complete remission and overall survival were best in the high-dose group, especially among patients with a favorable or an intermediate cytogenetic risk profile.

Data are scarce regarding the comparative efficacies of the inactivated (intramuscular administration) and live attenuated (intranasal administration) seasonal influenza vaccines. During the 2007–2008 influenza season, 1952 healthy young adults were enrolled in a randomized, double-blind, placebo-controlled study of these two vaccines. The inactivated vaccine was found to have an absolute efficacy of 68%, whereas the live attenuated vaccine had an absolute efficacy of 36%.

This double-blind trial was designed to determine whether rasagiline slows the progression of Parkinson's disease. As compared with delayed treatment, early treatment with rasagiline at a dose of 1 mg per day achieved benefits consistent with a disease-modifying effect, but 2 mg per day did not result in similar benefits.